Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - November 2014

14 November 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 3-6 November 2014. Topics discussed at the meeting:

  • PRAC recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)
  • PRAC recommends further assessment of risk of developing inhibitors with Kogenate Bayer/Helixate NexGen
  • PRAC advises informing about first case of PML in a patient treated with Tecfidera

Read PRAC's monthly report from the meeting 3-6 November 2014

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


...